` ZOM (Zomedica Corp) vs S&P 500 Comparison - Alpha Spread

ZOM
vs
S&P 500

Over the past 12 months, ZOM has underperformed S&P 500, delivering a return of -70% compared to the S&P 500's 12% growth.

Stocks Performance
ZOM vs S&P 500

Loading

Performance Gap
ZOM vs S&P 500

Loading
ZOM
S&P 500
Difference

Performance By Year
ZOM vs S&P 500

Loading
ZOM
S&P 500
Add Stock

Competitors Performance
Zomedica Corp vs Peers

Zomedica Corp
Glance View

Market Cap
53.9m USD
Industry
Health Care

Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company is headquartered in Ann Arbor, Michigan and currently employs 85 full-time employees. The company went IPO on 2013-10-28. The firm is engaged in creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. The firm's Diagnostics segment consists of TRUFORMA products. Its Therapeutics segment consists of PulseVet and Assisi products. Its TRUFORMA Bulk Acoustic Wave (BAW) point-of-care diagnostic platform is marketed with full diagnostic and thyroid panels for dogs and cats that include the only assays of these types available at the point of care to test for feline optimized TSH, endogenous ACTH, Free T4, and quantitative cortisol, along with a total T4 assay. The VetGuardian is its zero-touch vital signs remote monitoring system that enables contact-free, continuous monitoring of a pet's vital signs. The PulseVet is its electrohydraulic shockwave therapy platform. Its Assisi Loop line of products treats pain and inflammation through the delivery of targeted pulsed electromagnetic field focused energy (tPEMF).

ZOM Intrinsic Value
0.17 USD
Undervaluation 68%
Intrinsic Value
Price
Z
Back to Top